Genital Warts (Condyloma Acuminatum)- Epidemiology Forecast-2036

Genital Warts (Condyloma Acuminatum) Insights and Trends

• According to DelveInsight's estimates, in 2025, there were nearly 900,000 incident cases of Genital Warts (Condyloma Acuminatum) in the 7MM.
• Among the EU4 countries, Germany reported the highest number of incident cases of Genital Warts (Condyloma Acuminatum) in 2025. France followed with a significant number of cases. Spain had the lowest incidence among these countries. These figures highlight the varying levels of impact across the EU4 nations, emphasizing the need for targeted public health strategies and interventions to address the condition effectively.
• Genital HPV infections have an estimated prevalence of 10% to 20%, with clinical manifestations (genital warts) in 1%. The incidence of HPV infection has been increasing, with over 90% of sexually active men and 80% of sexually active women infected with HPV in their lifetime, and 80% of sexually active men and women becoming infected by age 45. About 80% of those infected are between 17 and 33 years old, with the peak age group being 20 to 24.
• Advancements in early detection and diagnostic technologies are significantly driving the genital warts market by enabling timely diagnosis, improving treatment outcomes, and reducing transmission rates. Genital warts, resulting from infection of the human papillomavirus (HPV), are one of the most prominently sexually transmitted infections (STIs) globally. Early detection exhibits a pivotal role in managing the disease efficiently and mitigating complications, encompassing the progression of HPV-associated cancers.

DelveInsight's 'Genital Warts (Condyloma Acuminatum)- Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Genital Warts (Condyloma Acuminatum), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Genital Warts (Condyloma Acuminatum) Understanding and Diagnosis Algorithm

Genital Warts (Condyloma Acuminatum) Overview

Human papillomavirus (HPV) is a small, nonenveloped, double-stranded DNA virus. Most of the HPV-related diseases and research are focused on HPV types within the alpha group. Individual types are further classified as high-risk (e.g., HPV16 and 18) and low-risk HPV (e.g., HPV6 and 11) based on oncogenic potential. E6 and E7 are the main oncoproteins, with E6 binding to p53.

Genital warts (also known as anogenital warts, condylomata acuminata, condylomas) are benign proliferative lesions caused by human papillomavirus (HPV) types 6 and 11, which are found in >95% of lesions. Genital warts (Genital Warts) are transmitted by having sexual contact with someone who already has them and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix. It is possible to get genital warts, HPV infection, even if they are not visible. Besides, they look like flesh-colored bumps that have a cauliflower-like appearance, and are usually flat, papular, or pedunculated growths on the genital mucosa, occurring in clusters.

Genital Warts can appear on the penis, vulva, vagina, cervix, groin, or thigh within weeks or months after sexual contact with an infected person. Potentially cancer-causing HPV strains are spread by sexual intercourse, anal sex, and oral sex.

Genital Warts (Condyloma Acuminatum) Diagnosis

Genital warts are typically diagnosed through a clinical examination by a healthcare professional, who inspects the genital, anal, or surrounding skin areas for characteristic wart-like growths caused by certain types of HPV, most commonly HPV types 6 and 11. In many cases, the appearance of the lesions is sufficient for diagnosis. If the diagnosis is uncertain, a biopsy may be performed to examine the tissue under a microscope and rule out other conditions. Additional testing for HPV is generally not required for diagnosing visible genital warts, although screening for other sexually transmitted infections (STIs) may be recommended based on individual risk factors and clinical findings. Early evaluation by a healthcare provider is important to ensure accurate diagnosis and appropriate management.

Genital Warts (Condyloma Acuminatum) Epidemiology

Key Findings from Genital Warts (Condyloma Acuminatum) Epidemiological Analysis and Forecast

• The total Incident Cases of Genital Warts in the United States were around 600,000 in 2025.
• In 2025, approximately 300,000 males and around 285,000 females in the United States were affected by Genital Warts.
• Among the EU4 countries, Germany reported the highest number of incident cases of Genital Warts in 2025, with approximately 80,000 cases. France followed with a significant number of cases, totaling around 60,000. Spain had the lowest incidence among these countries, with about 45,000 cases recorded.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of Genital Warts (Condyloma Acuminatum), explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Genital Warts (Condyloma Acuminatum) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by Geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Genital Warts (Condyloma Acuminatum)? What will be the growth opportunities across the 7MM concerning the patient population with Genital Warts (Condyloma Acuminatum)?
• What is the historical and forecasted Genital Warts (Condyloma Acuminatum)patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.